🔎 Trials Near Me

Domov › Adenokarcinom požiralnika › Virginia

Klinične študije za Adenokarcinom požiralnika v Virginia

13 študij za Adenokarcinom požiralnika išče udeležence na lokacijah v Virginia.

Mesta v Virginia

Uradno besedilo študije (angleško)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • University of Virginia Cancer Center, Charlottesville
  • Inova Schar Cancer Institute, Fairfax
  • Inova Fair Oaks Hospital, Fairfax
  • in še 6
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05677490

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Inova Schar Cancer Institute, Fairfax
  • Virginia Cancer Specialists, PC, Fairfax
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06324357

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  • Virginia Cancer Specialists, PC, Arlington
  • Virginia Oncology Associates, Chesapeake
  • Virginia Cancer Specialists, PC, Fairfax
  • in še 7
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07392892

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • NEXT Oncology Virginia, Fairfax
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07277413

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Blacksburg
  • Research Site, Fairfax
  • Research Site, Fort Belvoir
  • in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07431281

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Fairfax
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT07182149

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Virginia Cancer Specialists, Fairfax
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT06330064

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • Virginia Cancer Specialists, Fairfax
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 15. jul. 2026 · NCT06657144

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Virginia Cancer Specialists, Fairfax
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT04389632

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

  • Research Site, Fairfax
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 12. jun. 2026 · NCT07284186

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

  • NEXT Virginia, Fairfax
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 8. maj 2026 · NCT05954312

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.